Show simple item record

dc.contributor.authorAshoori, MR
dc.contributor.authorRahmati-Yamchi, M
dc.contributor.authorOstadrahimi, A
dc.contributor.authorFekri Aval, S
dc.contributor.authorZarghami, N
dc.date.accessioned2018-08-26T04:57:58Z
dc.date.available2018-08-26T04:57:58Z
dc.date.issued2017
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/38692
dc.description.abstractNowadays, diabetes mellitus (DM) along with its complications is considered as a fundamental problem in both developing and industrial countries, and is causing millions of people to suffer worldwide. Currently, diabetes mellitus is diagnosed traditionally or classically in the world by measuring fasting blood glucose and conducting oral glucose tolerance test. New alternatives are required for the treatment of diabetes mellitus, especially type 2 diabetes mellitus (T2DM), at its early levels due to the ineffective control of its development in patients. In recent years, by further identifying of molecular agents such as microRNAs (miRNAs), studies have focused on miRNAs in diabetes as well as in other diseases. These small non-coding RNA molecules have a significant role in the regulation of insulin gene expression and also, obesity problems. White adipose tissue, as an important tissue in obese subjects, is directly related to type 2 diabetes and its complications via synthesis of adipokines. Prevention and treatment of obesity should be noted since childhood. Our aim in this review is to briefly provide a new glance at types of potential biomarkers, which can be used as pharmacological targets for prevention and treatment of prediabetic subjects, and patients with T2DM.
dc.language.isoEnglish
dc.relation.ispartofBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
dc.subjectAdipokines
dc.subjectBiomarkers
dc.subjectBlood Glucose
dc.subjectDiabetes Mellitus, Type 2
dc.subjectGene Expression
dc.subjectHumans
dc.subjectInsulin
dc.subjectMicroRNAs
dc.subjectPrediabetic State
dc.titleMicroRNAs and adipocytokines: Promising biomarkers for pharmacological targets in diabetes mellitus and its complications.
dc.typearticle
dc.citation.volume93
dc.citation.spage1326
dc.citation.epage1336
dc.citation.indexPubmed
dc.identifier.DOIhttps://doi.org/10.1016/j.biopha.2017.07.059


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record